Health Care • Biotechnology: Pharmaceutical Preparations
$215.98 ▲ +8.15
(+3.92%)
MKT CAP: $14.02B • VOL: 1.22M
52W L $129 52W H $266
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$181
MEDIAN
$242
MEAN
$246
HIGH
$294
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE JAZZ TAPE
JAZZ // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $261.34 | $248.38 | 2025-02-14 | $196.54 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $272.13 | $254.86 | 2025-02-06 | $203.02 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $246.22 | $237.58 | 2025-01-29 | $207.34 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $220.30 | — | 2025-01-17 | $211.66 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $190.06 | $205.18 | 2025-01-09 | $192.22 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $257.02 | $224.62 | 2024-12-18 | $187.90 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $209.50 | $218.14 | 2024-12-04 | $200.86 | -4.3% | 48% | C |